Andrew Mortlock MA, DPhil

Dr. Mortlock joins Acerta from his duties as Vice President, Global Projects and Alliances, IMED Oncology at AstraZeneca, where he is responsible for all AstraZeneca’s small molecule oncology projects from the start of lead optimization through to the end of Phase IIb clinical studies. Over 25 years in roles of increasing responsibility at AstraZeneca, he previously led the Oncology research group at Alderley Park (UK) and Reims (France) which included chemistry, bioscience, and drug metabolism. He brings a wealth of medicinal chemistry, global development and project leadership experience involving kinase, protease, integrin, GPCR, nuclear hormone receptor, and protein-protein interaction targets.

Dr. Mortlock holds a first degree in chemistry and a Ph.D. in organic synthesis from the University of Oxford and carried out post-doctoral work at the University of California, Berkeley. He has been an author on more than 50 scientific papers, patents, and presentations.